We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current NLNK market cap is 7.04M. The company's latest EPS is USD -4.2999 and P/E is -0.21.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 497k | 512k | 691k | 527k | 7k |
| Operating Income | -7.55M | -8.84M | -8.04M | -9.64M | -8.93M |
| Net Income | -7.25M | -8.25M | -7.35M | -8.93M | -8.3M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 936k | 168k | 230k | 1.52M | 2.05M |
| Operating Income | -45.13M | -26.3M | -31.35M | -32.04M | -36.61M |
| Net Income | -42.99M | -5.66M | -30.43M | -31.06M | -34.03M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 79.21M | 72.29M | 63.73M | 56.37M | 47.75M |
| Total Liabilities | 11.5M | 12.71M | 11.21M | 12.71M | 12.26M |
| Total Equity | 67.71M | 59.58M | 52.52M | 43.66M | 35.49M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 96.79M | 129.03M | 100.31M | 72.29M | 40.64M |
| Total Liabilities | 17.91M | 12.46M | 11.34M | 12.71M | 13.33M |
| Total Equity | 78.88M | 116.57M | 88.98M | 59.58M | 27.31M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -20.8M | -26.62M | -9.2M | -15.88M | -23.7M |
| Investing | N/A | -11.36M | -2.46M | -1.38M | 4.57M |
| Financing | -346k | -821k | -309k | -883k | -1.32M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -30.21M | -23M | -29.65M | -26.62M | -31.1M |
| Investing | 77k | 116.65M | 25.97M | -11.36M | 10.74M |
| Financing | -59k | 75k | -192k | -821k | -576k |
| Market Cap | 7.04M |
| Price to Earnings Ratio | -0.21 |
| Price to Sales Ratio | 3.43 |
| Price to Cash Ratio | 0.2 |
| Price to Book Ratio | 0.26 |
| Dividend Yield | - |
| Shares Outstanding | 7.92M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.07 (7.1%) |
| Company Name | NewLink Genetics Corporation |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://lumos-pharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
